SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

GENEVA, SWITZERLAND / / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of ...

The financing round was jointly led by new investor Regeneron Ventures and current investor Deerfield Management.

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc. (“ Exo-TOP ”), the Company’s ...

Q4 2025 Earnings Call Transcript June 17, 2025 Beyond Air, Inc. beats earnings expectations. Reported EPS is $-0.09, ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...